What Conferences Are You Planning to Attend in Quarter 3 of 2024?

As we approach the third quarter of the year, Dermatology Times is beginning to shape a guide to 2024's summer and early fall dermatologic conferences and meetings.

Dermatologists are at the forefront of cutting-edge advancements, and your experiences attending conferences are invaluable. We want to harness your personal experiences to curate a comprehensive calendar that not only reflects the pulse of the dermatology landscape but is crafted by the very individuals shaping its future – you.

Have you uncovered a gem of a conference? Are you presenting groundbreaking research that your peers should not miss? Maybe your organization is hosting or organizing a conference of its own.

We want to hear about it. Your insights will not only elevate the conference experience for others but will also contribute to a dynamic and inclusive resource for the entire dermatology community.

Email us at DTEditor@mmgroup.com before June 26, detailing the conferences and meetings you plan to attend between July and September. Your contributions will help inform a reader-driven conference calendar, offering a curated roadmap for navigating the myriad of dermatologic meetings in 2024.

Want a glimpse at our previous conference calendars to see what we are looking for?

View our January calendar, February calendar, and March calendar, or our most recent, quarter 2 calendars: our April calendar, May calendar, and June calendar.

In the meantime, be sure to subscribe to our E-newsletters to receive dermatology and conference news straight to your inbox, review our conference listing page on our website, or view our recent conference coverage below.

Recent Conference News:

Looking Ahead to Advancements in Vitiligo and Atopic Dermatitis

David Rosmarin, MD, shares key points from phase 3 data of ruxolitinib for vitiligo, as well as highlights the potential for targeting the STAT pathway in upcoming atopic dermatitis therapeutics.

Exploring New Pathways in Atopic Dermatitis

Melinda Gooderham, MSc, MD, FRCPC, discusses potential new biologics for atopic dermatitis that target IL-22, IL-33, OX40, and more.

Ritlecitinib Shows Promising Results in Long-Term Trial

Researchers found patients with less than 95% hair loss at baseline reached median SALT score 2.4 or less, reflecting almost complete hair regrowth.

Quality of Life Improved in GPP in Effisayil 2 Trial

Poster presented at the SDPA conference reported Effisayil 2 data indicating spesolimab improved Dermatology Life Quality Index scores in patients with generalized pustular psoriasis.

Combining Systemic Therapies in Psoriasis and Atopic Dermatitis

James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.